Who are Double Umbilical Cord Blood Transplant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Allogeneic bone marrow transplantation, Haploidentical Bone Marrow Transplant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/double-umbilical-cord-blood-transplant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Double Umbilical Cord Blood Transplant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double Umbilical Cord Blood Transplant (Double Umbilical Cord Blood Transplant) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy / Hematopoietic stem cell transplant. Area: Oncology / Hematology.

phase 3 Cell therapy / Hematopoietic stem cell transplant Oncology / Hematology Biologic Live · refreshed every 30 min

Target snapshot

Double Umbilical Cord Blood Transplant (Double Umbilical Cord Blood Transplant) — Medical College of Wisconsin. Double umbilical cord blood transplant involves infusing two units of umbilical cord blood-derived hematopoietic stem cells to reconstitute the patient's bone marrow and immune system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Double Umbilical Cord Blood Transplant TARGET	Double Umbilical Cord Blood Transplant	Medical College of Wisconsin	phase 3	Cell therapy / Hematopoietic stem cell transplant
Allogeneic bone marrow transplantation	Allogeneic bone marrow transplantation	Medical College of Wisconsin	phase 3	Cell therapy / Hematopoietic stem cell transplantation
Haploidentical Bone Marrow Transplant	Haploidentical Bone Marrow Transplant	Medical College of Wisconsin	phase 3	Cell therapy / Hematopoietic stem cell transplant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy / Hematopoietic stem cell transplant class)

Medical College of Wisconsin · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Double Umbilical Cord Blood Transplant — Competitive Intelligence Brief. https://druglandscape.com/ci/double-umbilical-cord-blood-transplant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab